A starting price is useful only if you know what it buys and when you will pay again. That is the central budgeting problem with Omzo. Its homepage advertises semaglutide starting at $179 and tirzepatide starting at $279, while its terms describe initial and follow-up packages with different pricing language. The documents identify several included services, but they do not establish a medication supply period or billing interval. Those figures therefore cannot responsibly be converted into monthly treatment costs.
This review examines Omzo’s public documentation consulted October 19, 2026, rather than a purchased treatment experience. Omzo presents itself as a platform connecting adults with outside clinicians, primarily for access to compounded medication. Its strongest cost disclosure is the list of services bundled into its packages. Its weakest is the connection between those packages, the first checkout charge and subsequent payments. Brand-name fulfillment, refund channels and contact addresses also differ across pages, making a written, patient-specific quote particularly important before submitting an intake.
At a glance
- Homepage starting prices
- Semaglutide is advertised starting at $179 and tirzepatide starting at $279; the cited listings do not establish supply duration or a monthly billing period.Sources: [6]
- GLP-1 packages
- Terms describe the initial GLP-1 package as originally priced at $179 and the follow-up package as $299, including consultation, prescription, medication, shipping and medical support if needed.Sources: [3]
- Compounded tirzepatide packages
- The initial GLP-1 + GIP package is described as originally priced at $259; follow-up is $399. Neither has a documented supply period.Sources: [3]
- Platform responsibilities
- Omzo says it is neither a medical practice nor a pharmacy; outside clinicians decide whether to prescribe, and its primary program uses a compounding pharmacy.Sources: [6]
- Refund boundary
- Prescription orders generally become nonrefundable upon submission of initial medical intake, subject to stated exceptions. Refund requests must be made within 28 days of payment.Sources: [3]
Start with the charge, not an assumed monthly rate
Omzo publishes several dollar amounts, but none establishes a comparable monthly expense. The homepage uses “Starting at” for semaglutide at $179 and tirzepatide at $279. Its terms instead organize prices around initial and follow-up consultations. That distinction matters: a package may include medication without telling a buyer how much medication is supplied, how long it is intended to last or when another purchase becomes necessary. Neither a supply quantity nor a minimum commitment can be inferred from these labels.
The initial prices in the terms carry another qualification: “Originally priced at.” That wording does not establish the amount currently due at checkout or a continuing discount. The GLP-1 initial package is described this way at $179, and the GLP-1 + GIP initial package at $259. The latter does not match the homepage’s tirzepatide starting price of $279. The supplied pages do not explain whether these represent different offers, products or circumstances.
Before comparing Omzo with another service, obtain the current first charge, exact product and quantity, covered period, and next expected charge in writing. Our guide to understanding the first GLP-1 payment explains why an opening amount and a recurring budget are different questions. Omzo’s documents support reporting its published prices, not calculating an annual total, savings figure or stable monthly rate.
| Listing | Published amount | Important boundary |
|---|---|---|
| Homepage semaglutide | Starting at $179 | Supply duration and billing interval unspecified |
| Homepage tirzepatide | Starting at $279 | Relationship to the $259 initial package unexplained |
| Initial GLP-1 package | Originally priced at $179 | Current checkout charge and supply period not established |
| Follow-up GLP-1 package | $299 | No stated recurring interval |
| Initial GLP-1 + GIP package | Originally priced at $259 | Includes compounded tirzepatide; supply period unspecified |
| Follow-up GLP-1 + GIP package | $399 | Includes compounded tirzepatide; recurring interval unspecified |
Bundled services are clearer than the repeat-payment schedule
The package descriptions are relatively specific about included categories. Both initial and follow-up GLP-1 packages list a telehealth consultation, prescription, GLP-1 medication, shipping and ongoing medical support if needed. The GLP-1 + GIP packages list the same services while explicitly identifying compounded tirzepatide. Separately, the homepage says medication costs are included in fees Omzo collects and that Omzo pays the pharmacies. This describes bundled payment for the primary program, rather than a disclosed separate pharmacy bill.
However, the GLP-1 package wording does not identify the exact formulation, route, concentration or presentation that a particular patient would receive. The semaglutide marketing label does not fill those gaps. Nor does “support if needed” define appointment frequency, response times or a specified number of clinical contacts. Omzo also advertises personalized daily oral medication kits without identifying their ingredients in the supplied material. Those kits should not be treated as interchangeable with a clearly specified injectable prescription.
The $299 and $399 follow-up prices deserve attention, but they are not documented monthly renewals. The terms mention subscriptions without supplying a renewal calendar, minimum commitment or practical cancellation procedure. There is also no documented prepayment discount or multimonth plan. A useful comparison must separate what a program price includes from how often it is collected; Omzo supplies more information about the former than the latter.
Brand-name medication may sit outside the advertised bundle
Brand-name prescriptions present a separate financial question. The homepage disclosure says Omzo does not sell, dispense or ship branded medication. Under that description, a patient prescribed a branded product fills it at a pharmacy of their choice and pays all associated costs. That is materially different from the primary compounded program, for which Omzo says medication is included in collected fees. A shopper should not assume that a package advertisement covers a branded prescription.
The terms introduce a conflicting arrangement. They say Omzo offers fulfillment for FDA-approved branded medications under limited exceptions and, in those circumstances, manages dispensing and shipping. Availability depends on clinical approval and inventory, is not guaranteed, and all branded-medication costs remain the patient’s responsibility. The evidence does not reconcile this exception with the homepage’s categorical statement. Clarification should identify the actual dispensing pharmacy, who collects payment and whether any consultation fee remains separate.
Payment documentation is narrower than insurance documentation. Transactions are in U.S. dollars, and listed cards are MasterCard, Visa, American Express and Discover. Omzo says it does not store payment-card details. The consulted sources do not establish insurance billing, coverage assistance, prior authorization services or HSA/FSA acceptance. They also do not supply a general promotional discount: the terms say each promotion has its own conditions. A card-payment option should not be mistaken for confirmed insurance participation.
The refund boundary arrives before shipment
Omzo’s prescription refund policy makes the initial medical intake a consequential step. Once that intake is submitted, the terms consider the order processed and generally nonrefundable, citing medical and pharmacy resources. This boundary is earlier than dispatch or delivery. There are exceptions: the terms promise a full refund if the clinician determines during the initial consultation that the patient is medically ineligible, and for processing mistakes by Omzo such as duplicate or incorrect charges.
The medical-ineligibility exception has a significant condition. Omzo says it will not refund a patient who knowingly omitted or misrepresented a disqualifying condition in the initial questionnaire, as evidenced by contradictions with consultation disclosures. Supplement orders have a different boundary: they are considered processed and nonrefundable once payment is made. These are distinct rules, so someone purchasing supplements alongside prescription services should ask how each item appears on the bill and which policy applies.
Cancellation and reimbursement are not synonymous here. The terms say cancellation after a subscription charge prevents future charges but does not refund previously processed charges. Refund requests must be made within 28 days of original payment. The channel language conflicts: it first permits writing by email or postal address, then rejects channels other than email. The supplied email is masked and unusable. Our cancellation and refund guide provides context, but Omzo must supply the working channel and cancellation deadline.
Follow the money through the clinical handoff
The privacy notice identifies the business as Omzo Inc. Other disclosures say Omzo is not a medical practice or pharmacy, does not employ healthcare providers and does not directly provide medication. Clinical services come through third-party networks of U.S.-licensed clinicians, according to the company. Those clinicians assess medical history and decide whether to prescribe. This is a platform-and-partner structure, not documentation that Omzo itself delivers every service covered by the fee.
The described process starts with qualifying information collected by Omzo and passed to a healthcare provider. If appropriate, that provider invites the user to schedule an initial appointment through a patient portal Omzo does not operate. The provider requests additional information and supplies diagnosis, consultation and treatment. Omzo says the website assessment itself does not create a doctor–patient relationship. The consulted pages do not name the clinical networks, individual treating professionals or dispensing pharmacies, limiting advance scrutiny of those handoffs.
Services are intended for adults 18 and older. The terms restrict sales and shipping to the 50 U.S. states, excluding other territories and countries; that is not confirmation of actual clinical availability in every state. Specific BMI criteria, laboratory requirements and appointment timelines are not established. For budgeting, ask what happens to the charge if your state cannot be served or an appointment cannot be arranged, rather than assuming the medical-ineligibility refund answers every access problem.
Shipping is included, but delivery responsibilities need detail
Omzo advertises free, discreet delivery on all treatments and plain packaging. Its primary program is described as using a state-licensed sterile compounding pharmacy to prepare and ship medication. The terms say compounded medication will be shipped within the next 48 business hours after prescription approval during the telehealth consultation. That is a dispatch statement, not a promise of arrival within 48 hours, and it does not establish how quickly an initial appointment or prescription decision occurs.
Once a product is dispatched, the terms say shipping cannot be canceled or modified. The supplied documentation does not identify the carrier, tracking process, cold-chain arrangements, arrival window or replacement policy for loss or damage. Included shipping therefore answers one budget question without answering who absorbs the cost of a delivery problem. Before paying, request the process for an incorrect address, delayed parcel or unusable shipment, including which organization handles the complaint.
For an injectable GLP-1 product that arrives warm or with insufficient refrigeration, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. That is general regulatory guidance, not a finding about an Omzo shipment. It makes a reachable pharmacy and a clear escalation route practically important. FDA also reports medication-measurement and administration errors with compounded products; instructions should be clarified with the prescriber or pharmacist rather than reconstructed from a review.
Ongoing support needs a defined scope
Omzo advertises clinician-reviewed treatment plans, support through its app and a care team available by message. Its weight plans may include prescribed medication, nutrition guidance and daily habits; the conditional wording does not guarantee every component in every package. The homepage also mentions supplements delivered to the home. Buyers should establish whether supplements are optional purchases, what support accompanies them and whether nutrition services involve an actual scheduled interaction or general material.
Contact details are inconsistent. The contact page lists 6192 Coastal Highway, Lewes, DE 19958. The HIPAA policy lists 16192 Coastal Highway in Lewes and telephone number (332) 301-2274. The policy’s language about treatment also sits uneasily beside disclosures assigning treatment to outside providers. These discrepancies do not establish misconduct, but they weaken the clarity of where a billing dispute, records request or clinical concern should go. A working support route should be confirmed before purchase.
The privacy notice asks users to provide medical information only through the healthcare provider’s sites after Omzo’s initial questionnaire. Its health-data policy describes service, marketing and legal uses, subject to applicable law and consent where required. That makes the portal handoff worth understanding as well as the payment handoff. Ask which channel handles medical questions versus account questions, who can see messages, and what response window applies; no defined support-response or follow-up cadence appears in the supplied documentation.
A meaningful quote must identify the medication
Omzo acknowledges that compounded medications are not FDA approved and have not undergone FDA review for safety, efficacy or quality. It also says the facilities producing offered compounds are FDA registered. Facility registration and product approval are different claims; neither establishes FDA approval of Omzo’s program. The company expressly declines to claim that its compounded formulations are equivalent to, have the same active ingredient as or produce the same clinical outcomes as FDA-approved drugs.
FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence, but a low advertised price does not establish product equivalence either. Omzo’s missing formulation, route and presentation details prevent a product-matched comparison. A clinician should explain the proposed preparation and rationale, while the written quote should identify exactly what the pharmacy would dispense.
The practical next step is a complete written offer, not an assumed bargain. Request current initial and follow-up charges, medication details, supply duration, renewal authorization, support scope and refund instructions. Our prepayment question checklist can help organize that conversation. Omzo documents enough to identify its basic commercial model and several package prices, but not enough to determine the cost of a continuous course of care or compare it fairly with a clearly specified monthly program.
Questions & answers
Is Omzo’s $179 semaglutide price monthly?
The supplied pages do not establish that. The homepage says starting at $179, while the terms describe an initial GLP-1 package as originally priced at $179. Neither identifies a supply period or billing interval. Confirm the current charge, product quantity and date of any subsequent charge before treating it as a monthly budget.
Why does Omzo list both $279 and $259 for tirzepatide?
The homepage advertises tirzepatide starting at $279, but the terms describe the initial GLP-1 + GIP package with compounded tirzepatide as originally priced at $259. The documents do not explain the difference. Neither amount should be substituted for a confirmed checkout quote, and the $399 follow-up package has no stated recurring interval.
Does Omzo’s package include the pharmacy bill?
For its primary program, Omzo says medication costs are included in collected fees and that it pays the pharmacies. Its package terms also list medication and shipping. Branded medication is different: all associated medication costs remain the patient’s responsibility, and the pages conflict over whether Omzo can manage fulfillment under limited exceptions.
Can I get a refund if the clinician does not approve treatment?
The terms provide a full refund for medical ineligibility determined at the initial consultation, unless a disqualifying condition was knowingly omitted or misrepresented under the stated conditions. That exception should not be confused with a general satisfaction guarantee. Prescription orders otherwise become processed and generally nonrefundable when initial medical intake is submitted.
Will canceling an Omzo subscription reverse a charge?
Not under the general cancellation language: cancellation prevents future charges but does not refund charges already processed. The consulted pages do not explain the cancellation workflow or required notice before renewal. Ask for both before enrolling. Refund requests have a separate 28-day deadline, and the documented channel language needs clarification.
Does Omzo promise delivery within 48 hours?
No. Its terms describe shipping compounded medication within the next 48 business hours after prescription approval during the consultation. That is dispatch, not arrival. The supplied documentation does not establish a carrier or delivery deadline. Shipping cannot be canceled or modified after dispatch, so address and delivery questions should be resolved beforehand.
Our assessment
Omzo offers a recognizable bundled model: outside clinical evaluation, access primarily to compounded medication, shipping and support described within package fees. Publishing follow-up prices is useful, and the terms identify specific refund exceptions rather than leaving the subject entirely unaddressed. Those disclosures provide a starting point for a serious cost discussion. They do not yet provide a dependable ongoing budget. Supply duration, billing frequency, current introductory charges and cancellation mechanics remain unestablished. Conflicting tirzepatide listings, branded-medication responsibilities, refund channels and postal addresses add avoidable uncertainty. The appropriate conclusion is not that Omzo necessarily costs more or less than competitors, but that its published amounts are insufficient for that comparison. A prospective patient should obtain a written, product-specific quote and usable support details before crossing the intake-related refund boundary. If Omzo clearly resolves those points, its bundled offer becomes easier to evaluate; without them, the advertised starting price remains an incomplete description of the financial commitment.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.